CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. “With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter’s commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio. The early launch and adoption of our next generati
Related Questions
Did the company provide any updated guidance on cash flow, cash burn, and runway for the next 12‑18 months?
What revenue guidance did management provide for Q3 and the full fiscal year 2025, and how does it compare to prior guidance?
How did gross profit margin and operating expense trends change versus the prior quarter and year‑over‑year?
What are the key regulatory milestones and timelines for the next‑gen INTERCEPT product?
Did the reported revenue and earnings beat consensus analyst estimates?
How does the stock’s valuation (P/E, EV/EBITDA) compare to peers after this earnings release?
What are the potential catalysts or risks that could affect the stock price in the short term (e.g., regulatory approval, reimbursement decisions, competitive pressure)?
How does Cerus’ market share and competitive positioning compare with major competitors in the blood safety space?
How does the reported growth in INTERCEPT adoption across geographies compare to previous quarters and to competitor offerings?
What is the expected impact of the early launch of the next‑generation product on future revenue and gross margins?
What is the company's current debt level and any changes in financing or equity issuance plans?